Primary Aims -To utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific subprotocols of pathway-targeting agents in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders. -To determine the proportion of pediatric patients whose advanced tumors have pathway alterations that can be targeted by select anti-cancer drugs. -To determine the objective response rates (ORR; complete response + partial response) in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders harboring a priori specified genomic alterations treated with pathway-targeting agents. Secondary Aims -To estimate the progression free survival in pediatric patients receiving targeted therapies for advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders. -To obtain preliminary or additional information about the tolerability of targeted therapies in children with advanced cancers. -To provide preliminary estimates of the pharmacokinetics of targeted therapies in children with advanced cancers. -To obtain preliminary information on the response rate to targeted therapy in patients whose tumors lack actionable alterations as defined for the MATCH study, for selected agents for which efficacy is observed in the primary matched cohort.
Full Title
APEC1621MASTER-APEC1621SC: NCI-COG Pediatric MATCH Master and Screening Protocol